RECENT PAST NEWS IN MDR-TB

endTB Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options

New preventive treatment for children cuts the risk of drug-resistant tuberculosis by more than half

Ending TB Is Within Reach — So Why Are Millions Still Dying?

TAG's 2023 Pipeline Report: TB vaccines

Global Fund, Stop TB Partnership and USAID Announce New Collaboration with Danaher

Lancet Commission calls for renewed global response on TB

John Green & Grassroots Activists Pressure Danaher To Drop Price of Tuberculosis Test

Barely Contained Rage: An Open Letter to Danaher and Cepheid

What’s new in the TB section of the 2023 WHO Model Lists of Essential Medicines

The Big Deal with Diagnostics for Drug-Resistant TB

The resurgence of ‘ticking timebomb’ tuberculosis

Community and civil society demand their voices be heard in UN Political Declaration on TB

Why is a curable disease allowed to kill millions?

International consensus highlights the importance of molecular testing for MDR-TB

Sweet advance for treatment of children with multi-drug resistant TB

New safer and shorter drug-resistant TB treatment must be scaled up

MSF applauds Indian Patent Office’s rejection of J&J’s attempt to extend patent on lifesaving

World TB Day 2023 Campaign Toolkit

Sutezolid with 3-drug combo appears safe and effective in multidrug-resistant TB

TAG's TB Treatment Pipeline Report Published